Home Cart Sign in  
Chemical Structure| 1256349-48-0 Chemical Structure| 1256349-48-0

Structure of Chiauranib
CAS No.: 1256349-48-0

Chemical Structure| 1256349-48-0

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Chiauranib is an orally effective multi-target inhibitor primarily targeting angiogenesis-related kinases such as VEGFR and PDGFR. It possesses strong antitumor activity against cancer and shows potential in angiogenesis inhibition research.

Synonyms: Ibcasertib; CS2164

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Chiauranib

CAS No. :1256349-48-0
Formula : C27H21N3O3
M.W : 435.47
SMILES Code : O=C(C1=C2C=CC(OC3=CC=NC4=CC(OC)=CC=C34)=CC2=CC=C1)NC5=CC=CC=C5N
Synonyms :
Ibcasertib; CS2164
MDL No. :MFCD34179475
InChI Key :BRKWREZNORONDU-UHFFFAOYSA-N
Pubchem ID :49779393

Safety of Chiauranib

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319
Precautionary Statements:P501-P270-P264-P280-P302+P352-P337+P313-P305+P351+P338-P362+P364-P332+P313-P301+P312+P330

Related Pathways of Chiauranib

epigenetics
DNA
RTK

Isoform Comparison

Biological Activity

Description
Chiauranib (CS2164) is a multi-target inhibitor taken orally that acts against tumor angiogenesis. It effectively targets angiogenesis-related kinases (VEGFR1, VEGFR2, VEGFR3, PDGFRα, and c-Kit), the mitosis-related kinase Aurora B, and the chronic inflammation-related kinase CSF-1R, with IC50 values between 1-9 nM, exhibiting potent anticancer effects[1].

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT03166891 Ovarian Cancer PHASE1|PHASE2 COMPLETED 2019-03-20 Fudan University Shanghai Canc... More >>er Center, Shanghai, Shanghai, 200032, China Less <<
NCT03245190 Hepatocellular Carcinoma PHASE1|PHASE2 COMPLETED 2019-11-01 Zhongshan Hospital of Fudan Un... More >>iversity, Shanghai, Shanghai, 200032, China Less <<
NCT05346601 Healthy Volunteers PHASE1 COMPLETED 2022-06-28 The First Affiliated Hospital ... More >>of Suzhou University, Suzhou, Jiangsu, 21500, China Less <<
NCT05271292 Small Cell Lung Cancer|Advance... More >>d Solid Malignant Tumor Less << PHASE1|PHASE2 RECRUITING 2025-05-25 California Cancer Associates-E... More >>ncintas, Encinitas, California, 92024, United States|Providence/St. Joe Cancer Institute/Crosson Cancer Institute, Fullerton, California, 92835, United States|Winship Cancer Institute of Emory University, Atlanta, Georgia, 30322, United States|Dana Farber Cancer Institue, Boston, Massachusetts, 02215, United States|Karmanos Cancer Institute, Detroit, Michigan, 48201, United States|Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada, 89119, United States|Gabrail Cancer Center Research, Canton, Ohio, 44718, United States|OU Health, Oklahoma City, Oklahoma, 73104, United States|Sarah Cannon Research Center, Nashville, Tennessee, 37203, United States|North Houston Cancer Clinics, Huntsville, Texas, 77340, United States|Virginia Cancer Specialists, Fairfax, Virginia, 22031, United States Less <<
NCT02122809 Solid Tumors PHASE1 COMPLETED 2025-06-16 Cancer Hospital, Chinese Acade... More >>my of Medical Sciences, Beijing, Beijing, 100021, China Less <<
NCT03216343 Small Cell Lung Cancer PHASE1 COMPLETED 2023-05-15 Beijing Cancer Hospital, Beiji... More >>ng, Beijing, China Less <<
NCT05371899 Small Cell Lung Cancer COMPLETED 2024-03-18 The First Affiliated Hospital ... More >>of Suzhou University, Suzhou, Jiangsu, 21500, China Less <<
NCT05497843 Soft Tissue Sarcoma PHASE2 ACTIVE_NOT_RECRUITING 2024-12-30 Sun Yat-sen University Cancer ... More >>Center, Guangzhou, Guangdong, 510060, China Less <<
NCT03074825 Non-Hodgkin's Lymphoma PHASE1 TERMINATED 2019-02-14 Cancer Hospital, Chinese Acade... More >>my of Medical Sciences, Beijing, Beijing, 100021, China Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.30mL

0.46mL

0.23mL

11.48mL

2.30mL

1.15mL

22.96mL

4.59mL

2.30mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1

References

 

Historical Records

Categories